Long-term cardiac effects of modern treatment for Hodgkin’s lymphoma

Cardio-Oncology

Table 1 Classification and treatment in HL survivors

	AC + MRT (n = 132)	AC alone (n = 114)	p-value
Histology and stage
Age at diagnosis, years	28 ± 9	30 ± 10	0.09
Time from diagnosis to echocardiography, years	17.3 ± 2.8	16.2 ± 2.8	< 0.001
Classical Hodgkin’s Lymphoma	131 (99)	100 (88)	< 0.001
Nodular lymphocyte-predominant Hodgkin lymphoma	1 (1)	13 (11)	-
Stage I-IIA	83 (63)	60 (53)	0.10
Stage IIb-IV	49 (37)	54 (47)	-
Relapsing disease	23 (17)	14 (12)	0.26
Treatment
Cumulative anthracycline dose, mg/m2	200 (200–400)	220 (155–400)	0.81
Cumulative MRT dose, Gy	30 (30–35)	-	-
Vincristine/vinblastine	132 (100)	114 (100)	-
High-dose therapy with autologous stem cell support	20 (18)	12 (12)	0.24

Data expressed as n (%) for categorical parameters, mean ± SD for continuous, parametric parameters, and median (IQR) for continuous non-parametric parameters. P-value derived from the χ2-test for categorical variables, the students t-test for continuous parametric parameters and the Mann-Whitney U test for continuous, non-parametric parameters. BEP, bleomycin, etoposide, cisplatin; CBCT, cisplatin-based chemotherapy; CVB, cisplatin, vinblastine, bleomycin; EP, etoposide, cisplatin; MRT, mediastinal radio therapy

ISSN: 2057-3804